Pulse Biosciences (NASDAQ:PLSE – Get Free Report) released its earnings results on Wednesday. The company reported ($0.21) earnings per share (EPS) for the quarter, RTT News reports. During the same quarter in the previous year, the firm posted ($0.19) EPS.
Pulse Biosciences Stock Performance
Shares of PLSE stock traded down $1.51 during trading hours on Thursday, hitting $16.21. 28,685 shares of the company were exchanged, compared to its average volume of 199,472. The stock has a market capitalization of $993.51 million, a price-to-earnings ratio of -20.01 and a beta of 1.74. The business’s 50-day simple moving average is $17.70 and its two-hundred day simple moving average is $14.22. Pulse Biosciences has a one year low of $4.24 and a one year high of $22.69.
Analyst Ratings Changes
Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a report on Friday, September 20th.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Read More
- Five stocks we like better than Pulse Biosciences
- What is an Earnings Surprise?
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- How is Compound Interest Calculated?
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- Trading Stocks: RSI and Why it’s Useful
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
